(May 31, 2023) Manhattan Scientifics Inc., which provided the initial funding & currently owns more than 50 million shares of Imagion Biosystems Ltd. celebrates Imagion's remarkable progress in early cancer detection technology. Full release
(March 17, 2022) Manhattan Scientifics Inc., announces positive early results from Imagion Biosystems Cancer Diagnostic human study. Full release
(November 1, 2021) Manhattan Scientifics Inc. (OTC: QB), initially funded and is the current owner of more than 50 million shares of Imagion Biosystems Ltd. (IBX.AX). Full release
(May 26, 2021) MELBOURNE—Imagion Biosystems Limited(ASX:IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that the first patient has been enrolled in the MagSense® HER2 breast cancer Phase I first-in-human study. Full release
(March 11, 2021) NEW YORK--Manhattan Scientifics Inc. (OTCQB: MHTX) invested $30 million and a 10-year effort to commercialize the Imagion Biosystems (IBX: AX) super early, non- invasive, non-radioactive Cancer diagnostic, now “partnered” with MD Anderson Cancer Center, Houston. The company is awaiting regulatory approval to initiate human cancer trials. Full release
(February 25, 2021) Manhattan Scientifics Inc, an American medical technology incubator that seed funded IBX and then spun it out as a public company on the Australian stock exchange is pleased to provide this update on Imagion Biosystems 2020 Full-Year Results. Full release
(February 9, 2021) NEW YORK--Manhattan Scientifics Inc. a company that acquires, develops and commercializes life-enhancing technologies is pleased to announce year-end business updates on its two nano technologies for 2020: its Nano-Medicine Cancer and Nano-Medical Metal Alloy ventures. Full release
(December 17, 2020) Manhattan Scientifics Inc. (MHTX: OTCQB) announces that the first 15-person human study to provide a safety assessment for the company’s use of Nanoparticles for breast cancer detection is underway at Imagion Biosystems Inc. Trades as IBX.AX. Full release
(November 12, 2020) Manhattan Scientifics Inc., announces that University of New Mexico Tech Biology professor Dr. Rebecca Reiss has published new research that sheds light on how titanium implants interact with human tissue, potentially paving the way for a new generation of medical inserts that last longer. Full release
(November 10, 2020) Manhattan Scientifics Inc. provides a 45-minute interview with Imagion Biosystems Chairman/CEO Bob Proulx describing the very-early-cancer-diagnostic development that MHTX incubated and helped to go public on the Australian stock exchange: IMAGION BIOSYSTEMS LTD. Trades as IBX.AX. Full release
(August 18, 2020) Manhattan Scientifics Inc. announces one of America’s leading high quality material manufacturers for medical devices – a key supplier in the U.S. and abroad – is featured in Titanium Today a magazine published by the International Titanium Association. Full release
(August 13, 2020) Manhattan Scientifics Inc. (OTCQB: MHTX) owns 50+ Million shares of its former wholly-owned subsidiary cancer diagnostic company Imagion Biosystems Ltd. (AX: IBX). Full release
(July 1, 2020) Manhattan Scientifics Inc. announces one of America’s leading high quality material manufacturers for medical devices– a key supplier in the U.S. and abroad – is featured on the cover of The Journal of Materials. Full release
(February 26, 2020) NEW YORK--Manhattan Scientifics Inc., a principal & major shareholder of Imagion Biosystems Ltd. (IBX.AX) announces IMAGION’S initiation of manufacturing medical devices and pharma products to be used in first human clinical studies of very early cancer detection as approved by the FDA. Full release
(January 14, 2020) Manhattan Scientifics Inc. announces business updates on its two nano technologies. Full release
(July 25, 2019) NEW YORK--Manhattan Scientifics (OTC; QB MHTX) announces its former wholly owned sub Imagion Biosystems (ASX:IBX) Receives A$2 million in R&D Tax Incentives from the Australian Government (ATO). Full release
(July 22, 2019) NEW YORK--Manhattan Scientifics clarifies that it continues to own 64 million shares of Imagion Biosystems Ltd (ASX: IBX). Neither MHTX nor its management have sold any MHTX or IBX shares and have no present intention to do so. Full release
(July 18, 2019) NEW YORK--Manhattan Scientifics Inc.’s former wholly-owned subsidiary that was initially funded by MHTX, Imagion Biosystems Ltd (ASX:IBX) over a nine-year period has received confirmation from the Food and Drug Administration (FDA) that the MagSense System and Test for staging HER2 breast cancer has qualified for and been granted designation as a breakthrough device. The cancer diagnostic technology further develops the early work of physicist Edward R. Flynn, PhD. Full release
(July 9, 2019) NEW YORK--Manhattan Scientifics, Inc. today issued an update on the status of the company and its future plans. Full release
(May 2, 2019) NEW YORK--Manhattan Scientifics Inc., is pleased to announce that the company has completed an exclusive license and transfer of specialty machines to a large American metals manufacturer who provides specialty metals to the U.S. and global medical industry. The proprietary technology is designed to substantially improve and strengthen the bonding of medical prosthetics to human bone. Full release
(December 12, 2018) NEW YORK--Manhattan Scientifics Inc., today announced that the company is involved in discussions to license its nano-metals technology and related intellectual property to a medical industry metals manufacturer. Full release
(May 2, 2018) Manhattan Scientifics, Inc. today issued an update on its affiliates' progress regarding its Early Cancer Detection Diagnostic. Full release
(October 5, 2017) Manhattan Scientifics Inc. today issued an update on the status of the company and its technologies. The Company is a substantial owner of two Nanotechnologies. Full release
(June 22, 2017) Manhattan Scientifics Inc. (MHTX), Imagion Biosystems (IBX) and the National Institute of Health (NIH) collectively have invested over $20M to develop and commercialize the cancer diagnostic nanotechnology originally developed by Dr. Flynn. Full release